companyName

extensiveId

feedTypes

includeDividend

includeEstimates

includeOverview

includeOwnership

includeResearchContent

researchId

snapshotDate

CompanyName_Query

companySlug

CompanyMetaData

Company_query

company

query CompanyName_Query(
  $companyName: String!
  $extensiveId: ID
  $snapshotDate: String
  $researchId: ID
  $includeResearchContent: Boolean!
  $feedTypes: [ContentType!]!
  $includeEstimates: Boolean!
  $includeOverview: Boolean!
  $includeOwnership: Boolean!
  $includeDividend: Boolean!
) {
  ...CompanyMetaData_Ux1x9
  ...Company_query_1TiJKa
}

fragment AnalystData on Analyst {
  name
  pageUrl
  jobTitle
  imgUrl
}

fragment AuthorList on Content {
  __isContent: __typename
  id
  authors {
    __typename
    id
    name
    pageUrl
  }
}

fragment ChangePercentBlock_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      diff1mPercentage
      diff1yPercentage
      diff3yPercentage
      diffFromStartPercentage
    }
    id
  }
}

fragment CompactFeed_3NXCcw on Query {
  compactFeed: feedContent(companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...TeaserExtraCompact_content
        createdAt
        companies {
          viewerIsFollowing
          id
        }
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment CompanyAnalystQuery on Company {
  analysts {
    ...AnalystData
    name
    pageUrl
    jobTitle
    imgUrl
    id
  }
}

fragment CompanyCoverage_Company on Company {
  analysts {
    name
    id
  }
  isPayingCustomerOf
  isFormerCustomerOf
  isCorporateCustomer
  ...CompanyAnalystQuery
  defaultInstrument {
    ...TargetAndRecommendation_Company
    id
  }
}

fragment CompanyDescription_Company on Company {
  description
  websiteUrl
  name
}

fragment CompanyDisclaimer_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    isPayingCustomerOf
    isFormerCustomerOf
    id
  }
}

fragment CompanyDividendER_query on Company {
  name
  defaultInstrument {
    estimateData {
      reportingCurrency
    }
    dividendTransactions: estimateTransactions(first: 1, includeQuarters: false) {
      actualized {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
      estimates {
        year
        dividend
        dividendYield
        payoutPercentage
        sharePrice
      }
    }
    id
  }
}

fragment CompanyDividendNonER_query on Company {
  name
  defaultInstrument {
    nonERDividendSet: nonERCompanyNumberSet(includeQuarters: false) {
      year
      dividend
      dividendYield
      epsReported
      sharePrice
      currency
    }
    id
  }
}

fragment CompanyDividend_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...CompanyDividendER_query
    ...CompanyDividendNonER_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyFinancials_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    ...NonERCompanyNumbers_query
    ...CompanyNumbers_query
    defaultInstrument {
      coreId
      id
    }
    id
  }
}

fragment CompanyHeader_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    id
    companyInsref
    name
    viewerIsFollowing
    followersCount
    isCorporateCustomer
    hasPinpointData
    hasDividendHistory
    sector {
      sectorname
      industry
    }
    regions
    extensiveExists
    researchContentExists
    defaultInstrument {
      symbol
      priceData {
        tradeCurrency
        lastPrice
        diff1dPercentage
      }
      marketplace {
        name
      }
      estimates: estimateTransactions(first: 1, includeQuarters: false) {
        date
      }
      nonERCompanyNumberSet(first: 1, includeQuarters: false) {
        year
      }
      id
    }
    topOwners {
      holders {
        name
      }
    }
    transactions: insiderTransactions(filter: {types: [BUY, SELL, SUBSCRIPTION]}) {
      edges {
        node {
          date
          id
        }
      }
    }
  }
}

fragment CompanyInsiderTransactions on Company {
  name
  regions
  insiderTransactions(filter: {types: [BUY, EXERCISE_OF_SHARE_OPTION, PLEDGE, RECEPTION_OF_SHARE_PREMIUM, SELL, SUBSCRIPTION]}) {
    edges {
      node {
        insider
        position
        volume
        price
        date
        unit
        type
        relatedParty
        id
      }
    }
  }
}

fragment CompanyInvestorConsensus_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    companyInsref
    id
  }
}

fragment CompanyMetaData_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    description
    pageUrl
    defaultInstrument {
      estimateData {
        modelType
      }
      id
    }
    id
  }
}

fragment CompanyName_Slug on Company {
  slug
}

fragment CompanyNumbers_query on Company {
  name
  defaultInstrument {
    estimateData {
      modelType
      reportingCurrency
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      comparisonIndexName
      actualized {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        revenue
        revenueGrowth
        ebitda
        ebitAdjusted
        ebitReported
        preTaxProfit
        netEarnings
        epsReported
        epsAdjusted
        dividend
        payoutPercentage
        roePercent
        roiPercent
        enterpriseValue
        bookValue
        marketCap
        gearingPercent
        equityRatio
        dividendYield
        totalCosts
        loanLosses
        balanceSheetTotal
        tangibleBook
        cet1
        rwa
        sharePrice
        sharesTotal
        nav
        navPerShare
        opexOfNav
        totalShareholderReturn
        comparisonIndexReturn
        netDebtTotalAsset
        quarterlySharePrice
      }
    }
    id
  }
}

fragment CompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      companyTransactions: estimateTransactions(first: 1, includeQuarters: false) {
        actualized {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
        estimates {
          year
          revenue
          ebitAdjusted
          epsAdjusted
          dividendYield
          navPerShare
          totalShareholderReturn
        }
      }
      id
    }
    id
  }
}

fragment CompanyOwners on Company {
  regions
  topOwners {
    recordDate
    compareDate
    source
    holders {
      name
      capitalPercent
      votingPowerPercent
      totalShares
      positionChange
      totalSharesChange
      shareChange
      isNew
      isRemoved
    }
  }
}

fragment CompanyOwnership_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    name
    ...CompanyOwners
    ...CompanyInsiderTransactions
    id
  }
}

fragment CompanyPageBottom_query_2bVJwf on Query {
  ...GeneralFeed_data_3NXCcw
  ...CompactFeed_3NXCcw
  ...UpcomingEventsQuery_Ux1x9
  ...RiskRecommendMatrix_query_Ux1x9
  ...CompanyOverviewGraphs_query_Ux1x9
  ...NonERCompanyOverviewGraphs_query_Ux1x9
  company(companySlug: $companyName) {
    companyInsref
    ...ForumUpdates_Company
    defaultInstrument {
      coreId
      id
    }
    id
  }
  allFeed: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  main: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT, ANALYST_COMMENT, VIDEO, ARTICLE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  webcasts: feedContent(first: 1, companySlug: $companyName, filter: {hideUpcomingVideos: true, types: [WEBCAST]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  thirdPartyResearch: feedContent(first: 1, companySlug: $companyName, filter: {types: [THIRD_PARTY_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  releases: feedContent(first: 1, companySlug: $companyName, filter: {types: [STOCK_EXCHANGE_RELEASE, PRESS_RELEASE]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyPageTop_query_Ux1x9 on Query {
  ...StockChart_ChartQuery_Ux1x9
  ...LatestReports_query_Ux1x9
  company(companySlug: $companyName) {
    isFund
    name
    ...CompanyCoverage_Company
    ...CompanyName_Slug
    ...CompanyDescription_Company
    ...FundNumbers_Company
    ...ChangePercentBlock_Company
    ...KeyEstimateFigures_Company
    ...InvestmentCompanyKeyFigures_Company
    defaultInstrument {
      id
      estimateData {
        modelType
      }
    }
    analysts {
      name
      id
    }
    id
  }
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        id
      }
    }
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment Company_query_1TiJKa on Query {
  ...CompanyHeader_query_Ux1x9
  ...CompanyOwnership_query_Ux1x9 @include(if: $includeOwnership)
  ...CompanyFinancials_query_Ux1x9 @include(if: $includeEstimates)
  ...CompanyDividend_query_Ux1x9 @include(if: $includeDividend)
  ...CompanyInvestorConsensus_query_Ux1x9
  ...CompanyPageTop_query_Ux1x9 @include(if: $includeOverview)
  ...CompanyPageBottom_query_2bVJwf @include(if: $includeOverview)
  ...CompanyDisclaimer_query_Ux1x9
  ...Extensive_query_3u4Ry5
  ...ResearchContent_query_14bL89
}

fragment Extensive_query_3u4Ry5 on Query {
  company(companySlug: $companyName) {
    extensive(extensiveId: $extensiveId, snapshotDate: $snapshotDate) {
      publishedAt
      pageUrl
      pdfUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment ForumUpdates_Company on Company {
  name
  forum {
    threadUrl
    highlightedPosts {
      url
      author
      authorImgUrl
      text
      postedAt
      likesCount
    }
  }
}

fragment FundNumbers_Company on Company {
  defaultInstrument {
    isin
    symbol
    priceData {
      lastPrice
      ath
    }
    id
  }
}

fragment GeneralFeed_data_3NXCcw on Query {
  generalFeed: feedContent(first: 20, companySlug: $companyName, filter: {types: $feedTypes}) {
    edges {
      node {
        __typename
        id
        ...Teaser_content
        ...TeaserCompact_content
      }
      cursor
    }
    pageInfo {
      endCursor
      hasNextPage
    }
  }
}

fragment InvestmentCompanyKeyFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
    }
    estimateData {
      modelType
    }
    estimateTransactions(first: 1, includeQuarters: true) {
      actualized {
        year
        quarter
        sharesTotal
        marketCap
        nav
        navPerShare
        dividendYield
        quarterlySharePrice
      }
      estimates {
        year
        quarter
        dividendYield
      }
    }
    id
  }
}

fragment KeyEstimateFigures_Company on Company {
  marketData {
    marketCap
  }
  defaultInstrument {
    priceData {
      tradeCurrency
      dailyTurnover
      lastPrice
      marketCap
    }
    sector
    fundamentalData {
      ebit
      eps
      sales
      dividend
    }
    estimateData {
      modelType
      estimates {
        firstEstimateYear {
          year
          bookValue
          netSales
          dividendA
          epsAdjusted
          ebitAdjusted
          hybridLoan
          noOfShares
          netDebt
          mvMinorities
          mvAssociated
          roePercent
        }
      }
    }
    estimatesSharePrice: estimateTransactions(first: 1) {
      estimates {
        sharePrice
      }
    }
    id
  }
}

fragment LatestReports_query_Ux1x9 on Query {
  extensiveReport: feedContent(first: 1, companySlug: $companyName, filter: {types: [EXTENSIVE_COMPANY_REPORT]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysis: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku", "Arvonluojat"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
  analysisArvonluojat: feedContent(first: 1, companySlug: $companyName, filter: {types: [COMPANY_REPORT, EXTENSIVE_COMPANY_REPORT], tagNames_nin: ["Mallisalkku"]}) {
    edges {
      node {
        __typename
        createdAt
        pageUrl
        id
      }
    }
  }
}

fragment NonERCompanyNumbers_query on Company {
  name
  defaultInstrument {
    nonERNumberSet: nonERCompanyNumberSet(includeQuarters: true) {
      year
      quarter
      revenue
      ebitda
      ebitReported
      epsReported
      dividend
      sharesTotal
      roe
      roi
      enterpriseValue
      marketCap
      gearingRatio
      equityRatio
      dividendYield
      sharePrice
      currency
      evSales
      evEbitda
      evEbit
      pb
      netIncome
      ptp
    }
    id
  }
}

fragment NonERCompanyOverviewGraphs_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      overviewGraphsData: nonERCompanyNumberSet(includeQuarters: false) {
        year
        revenue
        ebitReported
        epsReported
        dividend
        dividendYield
        currency
      }
      id
    }
    id
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ResearchContent_query_14bL89 on Query {
  company(companySlug: $companyName) {
    slug
    researchContentFeed @include(if: $includeResearchContent) {
      __typename
      id
      ...Teaser_content
    }
    researchContentIds @include(if: $includeResearchContent)
    researchContent(researchId: $researchId) @include(if: $includeResearchContent) {
      researchId
      researchTitle
      publishedAt
      pageUrl
      content {
        id
        title
        lang
        slug
        htmlBody
        publishedAt
        createdAt
        changedAt
        isOutdated
      }
    }
    id
  }
}

fragment RiskRecommendMatrix_query_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      riskData: estimateTransactions(first: 1) {
        businessRisk
        valuationRisk
      }
      id
    }
    id
  }
}

fragment StockChart_ChartQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    isFund
    defaultInstrument {
      coreId
      id
      marketOpen
      marketClose
      marketplace {
        region
      }
      priceData {
        lastPrice
      }
      returns {
        day
        week
        month
        threeMonths
        sixMonths
        year
        threeYears
        fiveYears
        tenYears
        ytd
        total
      }
    }
    id
  }
}

fragment TargetAndRecommendation_Company on Instrument {
  estimateData {
    modelType
    researchCurrency
    estimates {
      date
      recommendation
      targetPrice
    }
  }
}

fragment TeaserCompact_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  isPremium
  pageUrl
  lang
  companies {
    ...CompanyTagList
    id
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
  ...AuthorList
}

fragment TeaserExtraCompact_content on Content {
  __isContent: __typename
  id
  title
  createdAt
  pageUrl
  lang
  companies {
    name
    pageUrl
    viewerIsFollowing
    id
  }
}

fragment Teaser_content on Content {
  __isContent: __typename
  __typename
  id
  type
  title
  createdAt
  pageUrl
  imgUrl
  isPremium
  lang
  companies {
    ...CompanyTagList
    id
  }
  publishers {
    imgUrl
  }
  authors {
    __typename
    id
  }
  ... on AnalystComment {
    preview
  }
  ... on Article {
    preview
  }
  ... on CompanyReport {
    preview
  }
  ... on ThirdPartyCompanyReport {
    preview
  }
  ... on QA {
    preview
  }
  ... on Video {
    preview
    liveTime
    videoDuration
  }
  ... on Webcast {
    preview
    liveTime
  }
  ...AuthorList
  ...Reactions
}

fragment UpcomingEventsQuery_Ux1x9 on Query {
  company(companySlug: $companyName) {
    defaultInstrument {
      calendarEvents(first: 10) {
        edges {
          node {
            date
            type
            period
            id
          }
        }
      }
      id
    }
    id
  }
}


name

description

pageUrl

defaultInstrument

companyInsref

viewerIsFollowing

followersCount

isCorporateCustomer

hasPinpointData

hasDividendHistory

sector

regions

extensiveExists

researchContentExists

topOwners

insiderTransactions

isPayingCustomerOf

isFormerCustomerOf

extensive

slug

feedContent

Faron Pharmaceuticals

Faron Pharmaceuticals Ltd: Remaining offer shares registered with Finnish Trade Register

Faron Pharmaceuticals Ltd: Registration of New Shares

Faron Pharmaceuticals Ltd: Approval of Share Subscriptions Based on Special Rights in connection with Amortisation of the First and Second Tranche Bonds

NOTICE OF FARON PHARMACEUTICALS LTD’S ANNUAL GENERAL MEETING

Faron Pharmaceuticals Ltd: New shares registered with Finnish Trade Register

Redeye: Faron Pharmaceuticals: Final outcome of EUR40m rights issue

Faron publishes final results of its EUR 40.1 million rights issue

Preliminary information on Faron's issue - funding secured until Q4'27

Inside Information: Faron publishes preliminary results of its successful rights issue

Faron Pharmaceuticals Ltd: Director Dealing

Faron Pharmaceuticals Ltd: Faron appoints new CTO to strengthen late-stage development activities

FARON PHARMACEUTICALS LTD: HOLDING(S) IN COMPANY

Redeye: Faron Pharmaceuticals (Interview): Funded beyond inflection points

Faron Company Presentation 17.3. at 18:00 EET

Faron: 

The Finnish Financial Supervisory Authority has approved Faron's rights offering prospectus

Redeye: Faron Pharmaceuticals: Final terms of EUR40m rights issue

Terms of Faron's rights offering have been published

Inside Information: Faron publishes the terms and conditions of a fully covered rights offering of approximately EUR 40 million and updates cash runway

Analyst

Antti Siltanen

First North Finland

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Review article from Yale researchers, with Zeidan as corresponding author, from yesterday, in a top publication (Journal Impact Factor: 82.2 (2024)) Nature Reviews Clinical Oncology. paywall A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions https://www.nature.com/articles/s41571-026-01141-2 Seen through “Bex eyes,” there are several factors involved:  Correction of immune imbalance Bone marrow inflammation, microenvironment Improving T-cell responses Patients are elderly and comorbid and thus benefit from drugs that do not have a high burden of side effects Combination therapies with HMAs are being developed  Etc. Let’s see how far these points take us, when the time comes. The latest review now gives r/r MDS mOS as 6–8 months. Translation of the summary by Bioengineer.org:   Summary Myelodysplastic Neoplasms 2026: Advances and Challenges Myelodysplastic neoplasms (MDS), formerly known as myelodysplastic syndromes, remain a significant challenge in hematology due to their heterogeneous nature and complex pathophysiology. These diseases comprise a group of clonal myeloid malignancies characterized by ineffective hematopoiesis, leading to peripheral blood cytopenias and an increased—though variable—risk of progression to acute myeloid leukemia (AML). Despite more than two decades of intensive research, treatments directly targeting the biology of MDS remain limited, and allogeneic hematopoietic stem cell transplantation (HSCT) is currently the only curative treatment. This review examines recent advances in understanding genetic mechanisms, refinements in diagnostics, risk classification, and new treatment strategies, as well as key obstacles to treatment development. The epidemiology of MDS highlights its prevalence in the elderly population: in the United States, the median age at diagnosis is approximately 76 years. This underscores the need for age-appropriate treatment strategies. The global aging of the population predicts an increase in the incidence and burden of MDS, increasing the need for better diagnostics and treatment innovations. Epidemiological estimates are complicated by shifting classification systems, which affect disease definition and participation in clinical trials. Furthermore, clinical and genetic heterogeneity complicates the establishment of reliable epidemiological trends, highlighting the need for standardized international registries. At the core of MDS pathogenesis are multifactorial genetic changes. New sequencing technologies have revealed a complex genome where recurrent somatic mutations occur in genes related to epigenetic regulation, the splicing machinery, signaling pathways, and transcription factors. In particular, mutations in the SF3B1, TET2, DNMT3A, ASXL1, and TP53 genes are common. This genetic diversity affects the disease phenotype and prognosis, as well as treatment responses and the identification of new drug targets. Additionally, hereditary predisposition syndromes, previously considered rare, are increasingly recognized as underlying factors in MDS, emphasizing the importance of broad genetic testing. Immune system dysfunction is a central part of MDS pathophysiology. The bone marrow microenvironment exhibits chronic inflammation, immune regulation disorders, and impaired immune surveillance, which promote clonal evolution and disease progression. Aberrant activation of innate immune pathways, such as Toll-like receptor-mediated signaling and inflammasome activity, maintains an inflammatory state. The role of adaptive immunity—particularly T-cell exhaustion and changes in regulatory T cells—is also increasingly clearly linked to ineffective hematopoiesis and treatment resistance. These findings open possibilities for immunomodulatory treatments. Diagnostics have evolved significantly by combining morphological assessment with advanced molecular and cytogenetic methods. While bone marrow morphology and cytogenetics remain central, molecular profiling has significantly improved diagnostic accuracy. This allows for the differentiation of MDS from other myeloid diseases and bone marrow failure states, and supports personalized prognostic assessment and treatment selection. The 2022 updates to the World Health Organization (WHO) and International Consensus Classification (ICC) systems reflect this development, but also bring challenges for longitudinal comparisons and trial design. Risk classification is a key part of MDS management. The Revised International Prognostic Scoring System (IPSS-R) is widely used and based on clinical, cytogenetic, and hematological factors. Newer models, such as the molecular-data-utilizing IPSS-M, provide even more accurate prognostic assessments. These help identify high-risk patients for early treatment and low-risk patients for whom supportive care is often sufficient. The use of dynamic biomarkers may enable real-time risk assessment in the future. The treatment landscape is evolving but still lags behind many other hematological malignancies. Hypomethylating agents (HMAs), such as azacitidine and decitabine, are the cornerstone of high-risk MDS treatment, but their efficacy is limited, and relapse or resistance is common. Combination therapies, where these drugs are combined with new targeted or immunological treatments, are being actively investigated. New drug classes include BCL-2 inhibitors, spliceosome modulators, and drugs targeting inflammatory pathways. The development of precision medicine and the increase in molecularly-guided trials promise to change clinical practices. Allogeneic stem cell transplantation remains the only curative treatment, but its use is limited by patient age, comorbidities, donor availability, and transplant-related risks. Outcomes have improved with advances in conditioning regimens, donor selection, and post-transplant care, but preventing recurrence and long-term survival remain challenges. Optimizing patient selection, for example through molecular-based risk classification, is a subject of active research. Furthermore, new strategies, such as adoptive immunotherapy and post-transplant maintenance therapies, are being developed to reduce recurrence. The evolution of classification systems brings challenges to clinical trials and epidemiological reporting. Changes in diagnostic criteria make it difficult to compare historical and new data. Clinical trial design requires flexible settings and biomarker-based inclusion criteria to effectively evaluate treatment efficacy. Standardizing the reporting of adverse events and treatment outcomes is also important. Research into the bone marrow microenvironment highlights its central role in the origin and progression of MDS. The interaction of clonal hematopoietic cells with the stroma, immune cells, and endothelial cells affects the course of the disease. Changes in the microenvironment, such as fibrosis, abnormal cytokine profiles, and disrupted cell-to-cell interactions, promote the development of ineffective hematopoiesis and clonal dominance. Understanding these mechanisms opens new therapeutic targets. Technological progress is accelerating MDS research. Single-cell sequencing, advanced computational models, and spatial transcriptomics reveal intra-tumoral heterogeneity and the complexity of the bone marrow ecosystem. These methods help identify new biomarkers, treatment targets, and resistance mechanisms. Multi-omic approaches integrate genomic, epigenomic, transcriptomic, and proteomic data, enabling more precise disease classification and personalized treatment. [/details]Despite progress, there are significant unmet needs in the field. The lack of reliable biomarkers for early diagnosis, disease monitoring, and predicting treatment response is a key challenge. Resistance to first-line treatments is common and poorly understood. Additionally, the treatment of elderly and multi-morbid patients requires personalized and less toxic solutions. International collaboration and multidisciplinary research are crucial to overcoming these obstacles. Future research focuses on treatments targeting individual molecular and immunological abnormalities. Combination therapies that affect multiple pathogenetic mechanisms simultaneously are promising. Integrating real-time data and patient-reported outcomes into treatment decisions improves personalized care. Furthermore, early intervention in clonal hematopoiesis before the development of actual MDS could represent a new preventive treatment strategy. In summary, the understanding of MDS is increasingly based on genetic changes, immune disorders, and microenvironmental influences. Although allogeneic stem cell transplantation remains a central curative treatment, the growing treatment landscape and molecular-level understanding point toward the era of precision medicine. Solving current challenges requires collaboration and technological development to improve treatment outcomes in this disease, which primarily affects elderly patients.

Faronin VP, operations, Joab Williamson, on this podcast episode: Designing Clinical Trials to Avoid Historical Failures in HR-MDS                    LinkedIn              The COG Review - Episode 10 | PBC Group - Organisers of the COG Series    🎙️ The COG Review Episode 10 - Designing Clinical Trials to Avoid Historical Failures: Practical Insights from COG UK 🎙️     🎗️ If you're working in oncology trial design, especially with difficult indications like high-risk myelodysplastic syndrome...                             Produced by PBC Group (Pharmaceutical Business Conference Group), a British conference organizer specializing in professional events in clinical research. It is particularly known for its COG Series (Clinical Outsourcing Group) event concept. A networker. This again relates to the pre-mortem analysis conducted to avoid needing a post-mortem. Specifically, regarding phase 3. You can listen here:           The COG Review: Building Better Clinical Studies              Designing Clinical Trials to Avoid Historical Failures in HR-MDS with Joab...    Quickly and easily listen to The COG Review: Building Better Clinical Studies for free!                             Or from all the services below:  Key points here:

BSH 2026 starts on April 19th, and Faron will have a poster presentation there with updated Bexmab f2 data.                   BSH 2026              Scientific Programme Overview    BSH 2026 will include the key pillars that have stood the programme in good stead for many years – outstanding plenary speakers, a wide range of parallel sessions, abstract presentations and industry educational symposia.

Faron hasn’t apparently published the DoR (duration of response) yet. Is the data mature enough now that data on this could be published on the 19th? Meaning, how long the treatment response lasts before the disease progresses. Considering the mechanism, bexmarilimab doesn’t just kill cells like AZA, but aims to modify the tumor’s immune microenvironment. So shouldn’t the DoR be “not reached” (over half of the responses still ongoing?) or significantly higher than AZA? Examples of drugs where a long DoR (“not reached”) has foreshadowed billion-dollar sales are Pembrolizumab, Nivolumab .. billion-dollar sales  .. (I checked those via ChatGPT). But at least it hasn’t been published yet, so are we at the “not reached” level?

I was just about to ask when the promised new survival data would be available. Apparently, it will be next week.

The investor calendar can be found here:                   Faron              Sijoittajakalenteri - Faron

@Paavo_Koivisto It would probably be good to update the shareholder holdings after the share issue. The total number of shares has been updated in the listing, but the shareholder holdings themselves have not. Because of this, at least the percentages look a bit funny:

Syrjälä Timo Kalevi

The European Innovation Council Equity Fund (EIC)

Faron Pharmaceuticals

0.48 EUR

+2.13 %